Ana García-Casas

Ana García-Casas

Auto-generated profile, based on publicly available information

Ana García-Casas

Departamento de Bioquímica y Biología Molecular; Facultad de Ciencias Químicas y Biológicas, Universidad Complutense, Madrid, Spain

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 October 2019 in Journal of Cell Science
Verified
Journal Article
Open access
PDF file
MLMar Lorente
Mar Lorente
AGAna García-Casas
Ana García-Casas
NSNélida Salvador
Nélida Salvador
AMAngélica Martínez-López
Angélica Martínez-López
EGEstibaliz Gabicagogeascoa
Estibaliz Gabicagogeascoa
SCSONIA CASTILLO-LLUVA
SONIA CASTILLO-LLUVA
Post-translational modifications directly control protein activity and, thus, they represent an important means to regulate the responses of cells to different stimuli. Protein SUMOylation has recently been recognised as one such modification, and it has been associated with various diseases, including different types of cancer. However, the precise way that changes in SUMOylation influence the tumorigenic properties of cells remains to be fully clarified. Here, we show that blocking the SUMO pathway by depleting SUMO1 and UBC9, or by exposure to ginkgolic acid C15:1 or 2-D08 (two different SUMOylation inhibitors), induces cell death, also inhibiting the invasiveness of tumour cells. Indeed, diminishing the formation of SUMO1 complexes induces autophagy-mediated cancer cell death through increasing the expression of Tribbles pseudokinase 3 (TRIB3). Moreover, we found that blocking the SUMO pathway inhibits tumour cell invasion by decreasing RAC1 SUMOylation. These findings shed new light on the mechanisms by which SUMO1 modifications regulate the survival, and the migratory and invasive capacity of tumour cells, potentially establishing the bases to develop novel anti-cancer treatments based on the inhibition of SUMOylation.

6 October 2020 in Cancer Research
Verified
Journal Article
Closed access
PDF file
ABAdrián Blanco-Gómez
Adrián Blanco-Gómez
LHLourdes Hontecillas-Prieto
Lourdes Hontecillas-Prieto
RCRoberto Corchado-Cobos
Roberto Corchado-Cobos
NGNatalia García
Natalia García
NSNélida Salvador
Nélida Salvador
SCSONIA CASTILLO-LLUVA
SONIA CASTILLO-LLUVA
SNAI2 overexpression appears to be associated with poor prognosis in breast cancer, yet it remains unclear in which breast cancer subtypes this occurs. Here we show that excess SNAI2 is associated with a poor prognosis of luminal B HER2+/ERBB2+ breast cancers in which SNAI2 expression in the stroma but not the epithelium correlates with tumor proliferation. To determine how stromal SNAI2 might influence HER2+ tumor behavior, Snai2-deficient mice were crossed with a mouse line carrying the ErbB2/Neu protooncogene to generate HER2+/ERBB2+ breast cancer. Tumors generated in this model expressed SNAI2 in the stroma but not the epithelium, allowing for the role of stromal SNAI2 to be studied without interference from the epithelial compartment. The absence of SNAI2 in the stroma of HER2+/ERBB2+ tumors is associated with: (i) lower levels of cyclin D1 (CCND1) and reduced tumor epithelium proliferation; (ii) higher levels of AKT and a lower incidence of metastasis; (iii) lower levels of angiopoietin-2 (ANGPT2), and more necrosis. Together, these results indicate that the loss of SNAI2 in cancer-associated fibroblasts limits the production of some cytokines, which influences AKT/ERK tumor signaling and subsequent proliferative and metastatic capacity of ERBB2+ breast cancer cells. Accordingly, SNAI2 expression in the stroma enhanced the tumorigenicity of luminal B HER2+/ERBB2+ breast cancers. This work emphasizes the importance of stromal SNAI2 in breast cancer progression and patients' prognosis.Significance: Stromal SNAI2 expression enhances the tumorigenicity of luminal B HER2+ breast cancers and can identify a subset of patients with poor prognosis, making SNAI2 a potential therapeutic target for this disease.

24 September 2020 in ACS Medicinal Chemistry Letters
Verified
Journal Article
Closed access
CBChristopher M. Brackett
Christopher M. Brackett
AGAna García-Casas
Ana García-Casas
SCSonia Castillo-Lluva
Sonia Castillo-Lluva
Brian BlaggBrian Blagg
Brian Blagg

31 March 2023
Verified
Other
Open access
ABAdrián Blanco-Gómez
Adrián Blanco-Gómez
LHLourdes Hontecillas-Prieto
Lourdes Hontecillas-Prieto
RCRoberto Corchado-Cobos
Roberto Corchado-Cobos
NGNatalia García
Natalia García
NSNélida Salvador
Nélida Salvador
SCSONIA CASTILLO-LLUVA
SONIA CASTILLO-LLUVA
Supplementary material and methods; Supplementary figures S1-S6; supplementary tables S1-S9

31 March 2023
Verified
Other
Open access
ABAdrián Blanco-Gómez
Adrián Blanco-Gómez
LHLourdes Hontecillas-Prieto
Lourdes Hontecillas-Prieto
RCRoberto Corchado-Cobos
Roberto Corchado-Cobos
NGNatalia García
Natalia García
NSNélida Salvador
Nélida Salvador
SCSONIA CASTILLO-LLUVA
SONIA CASTILLO-LLUVA
Supplementary material and methods; Supplementary figures S1-S6; supplementary tables S1-S9

31 March 2023
Verified
Other
Open access
ABAdrián Blanco-Gómez
Adrián Blanco-Gómez
LHLourdes Hontecillas-Prieto
Lourdes Hontecillas-Prieto
RCRoberto Corchado-Cobos
Roberto Corchado-Cobos
NGNatalia García
Natalia García
NSNélida Salvador
Nélida Salvador
SCSONIA CASTILLO-LLUVA
SONIA CASTILLO-LLUVA
SNAI2 overexpression appears to be associated with poor prognosis in breast cancer, yet it remains unclear in which breast cancer subtypes this occurs. Here we show that excess SNAI2 is associated with a poor prognosis of luminal B HER2+/ERBB2+ breast cancers in which SNAI2 expression in the stroma but not the epithelium correlates with tumor proliferation. To determine how stromal SNAI2 might influence HER2+ tumor behavior, Snai2-deficient mice were crossed with a mouse line carrying the ErbB2/Neu protooncogene to generate HER2+/ERBB2+ breast cancer. Tumors generated in this model expressed SNAI2 in the stroma but not the epithelium, allowing for the role of stromal SNAI2 to be studied without interference from the epithelial compartment. The absence of SNAI2 in the stroma of HER2+/ERBB2+ tumors is associated with: (i) lower levels of cyclin D1 (CCND1) and reduced tumor epithelium proliferation; (ii) higher levels of AKT and a lower incidence of metastasis; (iii) lower levels of angiopoietin-2 (ANGPT2), and more necrosis. Together, these results indicate that the loss of SNAI2 in cancer-associated fibroblasts limits the production of some cytokines, which influences AKT/ERK tumor signaling and subsequent proliferative and metastatic capacity of ERBB2+ breast cancer cells. Accordingly, SNAI2 expression in the stroma enhanced the tumorigenicity of luminal B HER2+/ERBB2+ breast cancers. This work emphasizes the importance of stromal SNAI2 in breast cancer progression and patients' prognosis.Significance:Stromal SNAI2 expression enhances the tumorigenicity of luminal B HER2+ breast cancers and can identify a subset of patients with poor prognosis, making SNAI2 a potential therapeutic target for this disease.